Результаты поиска

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol.

INTRODUCTION: Multiple myeloma (MM) is an incurable malignant neoplasm that accounts for approximately 1% of all cancers and 10% of haematological malignancies. Bortezomib is one of the most commonly used medications in first-line treatment and subsequent relapses, either as a single agent or in combination with other therapies. This study aims to assess the effects of bortezomib on the overall survival (OS), progression-free survival, overall response rate, time to next treatment, health-related quality of life, compliance, adverse events and treatment-related death in patients with MM. METH

Совпадение в полном тексте источника
… At the end of 1990, the therapy was based on corticosteroids, alkylating agents and anthracyclines (such as cyclophosphamide, cisplatin, dexamethasone/prednisone, doxorubicin, etoposide and melphalan), resulting in median overall survival (OS) of approximately 30 months, with a 5-year survival rate of … Bortezomib treatment was compared with treatment without bortezomib under different background therapies in the intervention and control groups, or bortezomib was compared with other therapeutic agents, for example, bortezomib plus melphalan plus prednisone (VMP) versus Rd, or bortezomib versus dexamethasone …

Treatment of multiple myeloma with selinexor: a review.

Over the last 20 years, breakthroughs in accessible therapies for the treatment of multiple myeloma (MM) have been made. Nevertheless, patients with MM resistant to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies have a very poor outcome. Therefore, it is necessary to explore new drugs for the treatment of MM. This review summarizes the mechanism of action of selinexor, relevant primary clinical trials, and recent developments in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma. Selinexor may be useful for the treatment

Совпадение в полном тексте источника
… Similar to selinexor, eltanexor also produces synergistic effects with dexamethasone. 87 Eltanexor acted synergistically with common anti-MM drugs, including bortezomib, carfilzomib, doxorubicin, melphalan, topotecan, and etoposide and induced apoptosis in numerous MM cell lines, as shown by Turner et … The result of a phase 1 study of selinexor in combination with high-dose melphalan and autologous hematopoietic cell transplantation for multiple myeloma. Blood 2019; 134: 3314. 95. Karam D, Gertz M, Lacy M, et al. …

Multiple myeloma: the (r)evolution of current therapy and a glance into future.

Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has translated to advances in diagnosis, prognosis, and response assessment, as well as informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight research areas of greatest promise to further improve patient outcome in the future.

Совпадение в полном тексте источника
… High-dose melphalan with ASCT remains a standard of care, and its role in the era of novel therapies is under evaluation in the IFM/DFCI 2009 DETERMINATION and FORTE clinical trials. … A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells . Clin Cancer Res . 2016 ; 22 ( 5 ): 1222 - 1233 . 26527748 10.1158/1078-0432.CCR-15-0489 PMC4775414 79. Zhao JJ Chu ZB Hu Y . …

Posterior Reversible Encephalopathy Syndrome: A Case Report With Contemporary Literature Review and Neuropathological Evidence From Autopsy.

Posterior reversible encephalopathy syndrome (PRES) is a neuro-radiological condition characterized by vasogenic edema in the parieto-occipital brain regions. Although typically reversible, some cases result in irreversible damage, particularly with delayed treatment. This study reviews 12 autopsy-confirmed cases and presents a novel case, emphasizing neuropathological findings that challenge the assumption of reversibility. Common pathological features include white matter edema, axonal swelling, and fibrinoid necrosis. Risk factors for PRES include hypertension (HTN), autoimmune diseases, re

Совпадение в полном тексте источника
… Acute lymphoblastic leukemia, tumor lysis syndrome | Prednisolone, cyclophosphamide, vincristine, doxorubicin | Greenwood MJ et al. [ 11 ], 2003 M | 60 | Recovery | HTN, status post bilateral renal transplant | N/A | Schiff D et al. [ 12 ], 2005 F | 70 | Death | Multiple myeloma, thrombocytopenia | Melphalan … , Vincristine, Cyclophosphamide, Adriamycin, Prednisolone | Okeda R et al. [ 13 ], 2007 F | 26 | Death | Myeloid sarcoma of breast, s/p BMT | Idarubicin, cytarabine, fludarabine, melphalan, antithymocyte globulin, tacrolimus, prednisolone, total body irradiation | Hayashi Y et al. [ 14 ], 2017 M | 74 …

Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report.

Multiple myeloma (MM) is an immunoglobulin-producing tumor of plasma cells, which occurs commonly in the elderly. The incidence of myocardial amyloidosis with MM is extremely low and early clinical manifestations are nonspecific. The diversity of clinical manifestations and first episode symptoms often cause misdiagnosis in young patients with myocardial amyloidosis following MM. In this study, we analyzed the clinical data of a young woman with MM and impaired cardiac function combined with echocardiography, electrocardiography (ECG), laboratory data, cell Congo Red staining, and other manife

Совпадение в полном тексте источника
… Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100(3):290–8. 10.1016/s0002-9343(97)89487-9. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C. et al. … Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100(3):290–8. doi: 10.1016/s0002-9343(97)89487-9. [21] Favia G, Lacaita MG, Laforgia PD. Oromaxillary amyloidosis. …

Chemotherapy-induced peripheral neuropathy.

Neuropathy is associated with side effects of frontline chemotherapeutics, which is a prominent therapy utilized in prevalent cancers. Peripheral neuropathy negatively impacts quality of life in cancer patients and survivors. It also affects the dose plan of the treatment, thereby limiting the efficacy of the treatment. We searched the electronic database PubMed for pre-clinically and clinically controlled trials reporting neuropathy of adverse effects, a result of chemotherapy in cancer patients. It was observed clearly that many reports provide clinical evidence to rapidly growing neuropathy

Совпадение в полном тексте источника
… To increase the efficacy of bortezomib, polymodal therapy has been implemented, whereby bortezomib was combined with several other agents, including dexamethasone alone, dexamethasone and thalidomide, prednisone alone, melphalan and prednisone and lenalidomide ( 33 ). … Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016;19:243–258. doi: 10.3111/13696998.2015.1115407. 34. …

Interpreting Randomized Controlled Trials.

This article describes rationales and limitations for making inferences based on data from randomized controlled trials (RCTs). We argue that obtaining a representative random sample from a patient population is impossible for a clinical trial because patients are accrued sequentially over time and thus comprise a convenience sample, subject only to protocol entry criteria. Consequently, the trial's sample is unlikely to represent a definable patient population. We use causal diagrams to illustrate the difference between random allocation of interventions within a clinical trial sample and tru

Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.

INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM. METHODS: De-identified data from the Flatiron Health MM

Совпадение в полном тексте источника
… Of the 1445 eligible LOT, 17.7% were other drug combinations (i.e., all drugs not recommended as regimens for the treatment of MM by the NCCN, which may include any PI, IMiD, anti-CD38 monoclonal antibody, melphalan, cyclophosphamide, or selinexor). … Matching-adjusted indirect treatment comparison to assess the comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, selinexor-dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class …

Эффективность и токсичность обработки захлестнувшей миеломы: систематический обзор и метаанализ.

ЦЕЛЬ: Множественная миелома (SMM) — медленное, асимптоматическое расстройство клеток плазмы. В ходе этого метаанализа была проведена оценка эффективности и безопасности новых методов лечения на основе использования агентов для SMM, особенно пациентов с повышенным риском. МЕТОДЫ: PubMed, Empase, Web of Science, Ovid MedLINE, Scopus и Clinical Procurements.gov были подвергнуты обыску на случайные контролируемые испытания (RCT) и неслучайные исследования, полученные в ходе 2003 в адрес 2024. Результаты: Nineteen были включены исследования, в том числе 5 РТС и 14 Неслучайные, одноручные испытания.

Совпадение в полном тексте источника
… Traditional treatments such as melphalan and prednisone have been shown to have no benefit in overall survival for early therapy and have major side effects [ 7–9 ]. … Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993;50(2):95–102. doi: 10.1111/j.1600-0609.1993.tb00148.x. 8. Gao M, Yang G, Tompkins VS, et al. …

Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.

AbstractQuadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was to conduct a systematic review and meta-analysis to measure the efficacy and toxicity of quadruplet regimens used in NDMM. Embase, MEDLINE, Web of Science, Cochrane Library, clinical trial registries, and meeting libraries from inception to 24 January 2024, in addition to American Society of Clinical Oncology conference abstracts 2024, were searched us

Совпадение в полном тексте источника
… Third arm with bortezomib, melphalan, and prednisone followed by lenalidomide excluded. Table 1. … Third arm with bortezomib, melphalan, and prednisone followed by lenalidomide excluded. …

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.

The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, parallel group, multi-centre phase II trial in patients with relapsed MM after prior treatment with thalidomide, lenalidomide, and a proteasome inhibitor (ISRCTN58227268), with the primary objective to test whether ICD has improved clinical activity compared to cyclophosphamide and dexamethasone (CD) in terms of progression-free survival (PFS). Between January 2016 and Dece

Совпадение в полном тексте источника
… The combination of bortezomib or carfilzomib with dexamethasone and melphalan (VMP, KMP) leads to high response rates in NDMM and RRMM [ 3 , 4 ]. Cyclophosphamide, when given in combination with dexamethasone and bortezomib or carfilzomib is also effective in NDMM and RRMM [ 5 – 12 ]. … Facon T Lee JH Moreau P Niesvizky R Dimopoulos M Hajek R Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma Blood. 2019 133 1953 63 10.1182/blood-2018-09-874396 30819926 4. …

Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??

IntroductionThe optimal treatment for young patients with high-risk newly diagnosed multiple myeloma (NDMM) remains a challenge.MethodsWe retrospectively evaluated 58 NDMM patients younger than 55 years treated in our center from 2010 to 2021 with the current recommended protocols.ResultsAfter a median follow-up of 48 months, median overall survival (OS) was not reached; however, approximately 25% of them died within 4 years after diagnosis. Advanced disease stage, presence of extramedullary disease, elevated LDH, and less than very good remission before autologous hematopoietic stem-cell tran

Совпадение в полном тексте источника
… 24 27 MM subtype IgG 83 41 42 IgA 14 5 9 FLC 16 10 6 ns k-LC 78 39 39 λ-LC 35 17 18 Nonsecretory 2 1 1 CCT VRD 53 26 27 VCD 31 17 14 VTD 7 5 2 VD 16 10 6 ns RD 5 — 5 Other 4 — 4 ORR Yes 96 51 45 ns No 20 7 13 CR + sCR 43 22 21 ns ≥VGPR 71 36 35 <VGPR 46 23 23 AHSCT (conditioning regimen: high-dose melphalan … Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study …

Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.

Due to the curative potential and improvement in progression-free survival (PFS), high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for several hematologic malignancies, such as multiple myeloma, and lymphomas. ASCT typically involves support with blood product transfusion. Thus, difficulties arise when Jehovah's Witness patients refuse blood transfusions. In order to demonstrate the safety of performing "bloodless" ASCT (BL-ASCT), we performed a retrospective analysis of 66 Jehovah's Witnesses patients who underwent BL-ASCT and 1

Совпадение в полном тексте источника
… Patients were admitted prior to stem cell transplantation and given one of several conditioning regimens, including: melphalan, BEAM, R-BEAM, carboplatin + etoposide, carboplatin + etoposide + thiotepa, total body irradiation + cyclophosphamide, total body irradiation + cyclophosphamide + etoposide, … MM multiple myeloma, NHL non-Hodgkin’s lymphoma, HL Hodgkin’s lymphoma, CNS GCT central nervous system germ cell tumor, ALL acute lymphoblastic lymphoma, Mel melphalan, Carbo carboplatin, Thio thiotepa, VP16 etoposide, R rituximab, ARDS acute respiratory distress syndrome, GI gastrointestinal, A fib …

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.

Multiple myeloma (MM) is one the most common hematological malignancies, and despite the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies, the need for novel agents is prominent. Selinexor is a first-in-class, oral, selective inhibitor of exportin-1 (XPO1), a vital protein for the exportation of more than 200 tumor suppressor proteins from the nucleus. Both in solid tumors and hematologic malignancies, selinexor-mediated inhibition of nucleus export seems to effectively lead to cancer cell death. Selinexor in combi

Совпадение в полном тексте источника
… XPO1 inhibition increases the melphalan-induced DNA damage by impairing the DNA repairing mechanisms in myeloma cells. 27 Moreover, XPO1 inhibitors may enhance the anti-myeloma activity of doxorubicin. … The synergistic effect of melphalan and XPO1 inhibition in pre-clinical models of multiple myeloma. Blood . 2016;128(22):5662. doi: 10.1182/blood.V128.22.5662.5662 28. Garg M, Kanojia D, Mayakonda A, et al. …

AL Amyloidosis: Unfolding a Complex Disease.

Light chain (AL) amyloidosis is a rare plasma cell dyscrasia. An estimated 12,000 people live with the disease in the United States. AL amyloidosis occurs from the misfolding of proteins that deposit in organs (heart, kidneys, digestive tract, tongue, lungs, and nervous system), leading to progressive organ damage and impairment of quality of life. The treatment of AL amyloidosis has improved greatly over the past several years, with new treatments currently in development. This article will focus on the pathophysiology, diagnosis, and treatment of AL amyloidosis.

Совпадение в полном тексте источника
… Earlier treatment modalities for AL amyloidosis included chemotherapy with melphalan and prednisone, which neither produced remarkable response rates (RR) nor changes in overall survival (OS; Merlini, 2017 ). … Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted approach. …

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide. Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m2 on D1 and D15 plus DXM 40 mg on D1, D8, D15, and D22 (arm A, n = 171) or DXM 40 mg on D1, D8, D15, and D22 (arm B, n = 84) q4wk. The primary endpoint was progression-free survival (PFS). Median PFS without disease progression (PD) confirmation (IRC asse

Совпадение в полном тексте источника
… was defined as disease that was non-responsive while on salvage therapy or progressed within 60 days of the last therapy in patients who had achieved MR or better at some point before progressing e The most common previous agents were bortezomib (98.4% of patients), lenalidomide (97.6%), DXM (97.6%), melphalan … Beyond these, there are few options for salvage treatment, which are limited to re-challenge with a previously used treatment (alone or in combination with corticosteroids or other novel agents), use of older drugs (e.g., thalidomide, melphalan, vincristine, doxorubicin, etoposide, bendamustine, and …

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature.

Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and benign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor like shrinking family sizes in many societies, underrepresentation of the ethnic minorities in the registries, genetic variability for some races, and significant delays in obtaining stem cells after starting the search. So there is a considerable need to develop alternate donor stem cell sources. The rapid and near universal availability of the haploidentical

Совпадение в полном тексте источника
… MDACC used fludarabine, melphalan 100–140 mg/m 2 based regimen with thiotepa, or TBI 200 cGy. Eighty-four patients had a BM graft except 4 pts. (95%). Overall, for the entire cohort, relapse rate was 32% and PFS was 42.3%. … When they compared 32 patients with AML/MDS who received BM haploidentical SCT with MRD and MUD who underwent matched transplantations and received melphalan-based conditioning regimen and conventional GVHD prophylaxis, results were comparable. …

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… KRd induction was followed by tandem high-dose melphalan (HDM) and ASCT, four cycles of KRd consolidation, and then carfilzomib-lenalidomide maintenance (carfilzomib 27 mg/m 2 on days 1,2,15,16 and lenalidomide 10 mg on days 1–21) until progression or undue toxicity. … KRd indicates carfilzomib, lenalidomide, and dexamethasone, G-CSF granulocyte colony-stimulating factor, HDM high-dose melphalan, ASCT autologous stem cell transplantation, RIC reduced-intensity conditioning, ALLO-SCT allogeneic stem cell transplantation, and KR carfilzomib and lenalidomide. 23 of the …

"Catch-Up Vaccinations Post-Stem Cell Transplant: A case series and review of the literature".

Stem cell transplantation (SCT), including autologous and allogeneic approaches, is a potentially curative therapy for various hematologic malignancies and selected non-malignant disorders. Autologous stem cell transplantation (ASCT) is an established curative treatment for hematologic malignancies, including Hodgkin lymphoma (HL). Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma (MM), but infectious complications remain a major challenge. Vaccination is an essential strategy to reduce the risk of vaccine-preventable infections following transplant. This case series describes immunocompromised

Совпадение в полном тексте источника
… He subsequently received four cycles of IGEV (ifosfamide, gemcitabine, vinorelbine, prednisone) chemotherapy in Germany starting in March 2020, followed by BEAM (carmustine [BCNU], etoposide, cytarabine [Ara-C], melphalan) conditioning and ASCT on June 24, 2020, with a CD34+ cell dose of 10.7 × 10⁶ cells … He underwent BEAM (carmustine [BCNU], etoposide, cytarabine [Ara-C], and melphalan) conditioning followed by ASCT in September 2021, complicated by mucositis and febrile neutropenia, and received 11 cycles of post-transplant brentuximab consolidation before discontinuation due to neuropathy and drug …

Неохваченный ультрафрейл: отдельная подгруппа нетрансплантированных новых пациентов с множественными миеломами, имеющих более низкий клинический результат.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… As a result, clinical outcomes may differ markedly within this subgroup. 1 Indeed, a post hoc analysis of the HOVON‐123 trial, in which patients were treated with nine cycles of dose‐adjusted melphalan, prednisone, and bortezomib, revealed that the overall survival (OS) of frail patients with an IMWG‐FI … Feasibility and efficacy of dose adjusted melphalan–prednisone–bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed multiple myeloma; the non‐randomised phase II HOVON 123 study . Blood . 2016 . 8 Facon T , Dimopoulos MA , Meuleman N , et al. …